Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bula

Showing results (351-360 of 442) with videos related to

Pageof 45
Sort By:
Scientific Data|August 26, 2021
Proteomic profiling dataset of chemical perturbations in multiple biological backgroundsDeborah O Dele-Oni, Karen E Christianson, Shawn B Egri, et al.
Molecular Psychiatry|September 30, 2024
Dysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoidsDorit Trudler, Swagata Ghatak, Michael Bula, et al.
Nature|November 17, 2022
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytesJoel W Blanchard, Leyla Anne Akay, Jose Davila-Velderrain, et al.
BMC Musculoskeletal Disorders|November 30, 2021
OF-Pelvis classification of osteoporotic sacral and pelvic ring fracturesBernhard W Ullrich, Klaus J Schnake, Ulrich J A Spiegl, et al.
BMC Health Services Research|August 19, 2025
Leveraging infant visit PrEP screening INtegration & tasK shifting to improve post-partum HIV prevention in Malawi (LINK): a cluster-randomized trial evaluation of a postpartum HIV prevention package among breastfeeding women in MalawiSarah E Rutstein, Valerie A Lucas, Mina C Hosseinipour, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
The Lancet. Infectious Diseases|June 22, 2023
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trialIvan T Lee, Catherine A Cosgrove, Patrick Moore, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 45

Showing results (351-360 of 442) with videos related to

Sort By:
Pageof 45
Scientific Data|August 26, 2021
Proteomic profiling dataset of chemical perturbations in multiple biological backgroundsDeborah O Dele-Oni, Karen E Christianson, Shawn B Egri, et al.
Molecular Psychiatry|September 30, 2024
Dysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoidsDorit Trudler, Swagata Ghatak, Michael Bula, et al.
Nature|November 17, 2022
APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytesJoel W Blanchard, Leyla Anne Akay, Jose Davila-Velderrain, et al.
BMC Musculoskeletal Disorders|November 30, 2021
OF-Pelvis classification of osteoporotic sacral and pelvic ring fracturesBernhard W Ullrich, Klaus J Schnake, Ulrich J A Spiegl, et al.
BMC Health Services Research|August 19, 2025
Leveraging infant visit PrEP screening INtegration & tasK shifting to improve post-partum HIV prevention in Malawi (LINK): a cluster-randomized trial evaluation of a postpartum HIV prevention package among breastfeeding women in MalawiSarah E Rutstein, Valerie A Lucas, Mina C Hosseinipour, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
The Lancet. Infectious Diseases|June 22, 2023
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trialIvan T Lee, Catherine A Cosgrove, Patrick Moore, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 45